Anti-Coagulants - Taiwan

Taiwan

Highlights

The Anti-Coagulants market in Taiwan is projected to achieve a revenue of US$117.90m in 2024.
It is anticipated that the revenue will experience an annual growth rate (CAGR 2024-2029) of 7.36%, leading to a market volume of US$168.20m by 2029.
In terms of global comparison, United States is expected to generate the highest revenue in the Anti-Coagulants market, reaching US$16.74bn in 2024.
Taiwan is experiencing a growing demand for novel oral anticoagulants due to their convenience and effectiveness in preventing thrombotic events.

Key regions:

Market definitionIn-Scope/Out-of-scopeMarket structureReportsMethodology

The Anti-Coagulants market in Taiwan has seen significant growth over the past few years, driven by a number of factors.

Customer preferences: Patients in Taiwan are increasingly seeking out Anti-Coagulants as a preventative measure for conditions such as stroke and heart attack. Additionally, an aging population has led to an increase in demand for drugs that can help manage chronic conditions such as atrial fibrillation.

Trends in the market: One trend that has emerged in the Taiwanese Anti-Coagulants market is the increasing popularity of direct oral anticoagulants (DOACs) over traditional Vitamin K antagonists (VKAs). DOACs are seen as a more convenient option for patients, as they do not require frequent monitoring or dietary restrictions. This shift towards DOACs has been observed in other markets as well, but is particularly pronounced in Taiwan.Another trend in the market is the growing use of combination therapies, which involve the use of multiple drugs to achieve better outcomes. For example, some patients may be prescribed both an Anti-Coagulant and an antiplatelet drug to reduce the risk of blood clots.

Local special circumstances: Taiwan has a well-developed healthcare system that provides universal coverage to its citizens. This has helped to support the growth of the Anti-Coagulants market by ensuring that patients have access to the drugs they need.Additionally, there is a high level of awareness among Taiwanese patients about the importance of preventative healthcare, which has helped to drive demand for Anti-Coagulants.

Underlying macroeconomic factors: Taiwan has a rapidly aging population, which is expected to continue to grow in the coming years. This demographic shift is expected to drive demand for drugs that can help manage chronic conditions such as atrial fibrillation.Furthermore, Taiwan has a strong pharmaceutical industry that is focused on developing innovative drugs to meet the needs of patients. This has helped to support the growth of the Anti-Coagulants market by ensuring that there are a wide range of treatment options available to patients.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.